Development of key performance indicators to evaluate centralized intake for patients with osteoarthritis and rheumatoid arthritis

"Arthritis stakeholders have proposed 28 KPIs [Key Performance Indicators] that should be used in quality improvement efforts when evaluating centralized intake for OA [osteoarthritis] and RA [rheumatoid arthritis]. The KPIs measure five of the six dimensions of quality and are relevant to patients, practitioners and health systems."

Development of key performance indicators to evaluate centralized intake for patients with osteoarthritis and rheumatoid arthritis
CE Barber et al.
Arthritis Research & Therapy 2015, 17:322 doi:10.1186/s13075-015-0843-7

Read more here. 

Medicine optimisation can cut the costs of long term conditions

"Medicines optimisation can cut waste, emergency admissions and the cost of long term conditions. But a review of rheumatoid arthritis care reveals how far it has to go"

Medicine optimisation can cut the costs of long term conditions
M Shelley
Health Service Journal Supplement
June 2015

Read more here.

Implementing a patient-initiated review system in rheumatoid arthritis

"This study forms part of a service evaluation of a system wide implementation of a patient initiated review appointment system which we have called Direct Access (DA). The aim was to explore the experiences of patients and staff of a DA system in order to understand the process of the implementation and to identify potential improvements."

Implementing a patient-initiated review system in rheumatoid arthritis: a qualitative evaluation
S Child, VA Goodwin, MG Perry, CA Gericke, R Byng
BMC Health Services Research 2015, 15:157  doi:10.1186/s12913-015-0837-9

Read more here.

European guideline variations and access to innovative therapies for rheumatoid arthritis

"This report usefully documents the variation in treatment across 12 European countries in the treatment of Rheumatoid Arthritis (RA), and notes the large cost imposed on societies by this disease."

A common disease with uncommon treatment: European guideline variations and access to innovative therapies for rheumatoid arthritis
T Hockley, J Costa-Font
Policy Analysis Centre Limited
June 2012

Read more here.